- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC
Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Sandip P. Patel, MD, a professor of medicine in the Department of Medicine at the University of California, San Diego (UCSD) and a medical oncologist at the UCSD Moores Cancer Center, discussed toxicities to be aware of when using immunotherapy-based combination regimens in patients with advanced non–small cell lung cancer (NSCLC). He also highlighted the current role of antibody-drug conjugates in the NSCLC treatment paradigm, as well as ways this class of agents may evolve in the future.
Related Content:
